Cardiac surgeons at Englewood Health this past March performed the state’s first aortic valve replacement using the Inspiris Resilia artificial valve.
The patient was a 53-year-old male who, aside from having a damaged aortic valve, was otherwise healthy.
The surgeons used the Inspiris Resilia artificial valve, a technology developed by California-based Edwards Lifesciences Corp. and recently approved by the U.S. Food and Drug Administration.
The state-of-the-art artificial valve is made of pericardial tissue from cows and has two distinct features: early indicators show anti-calcification properties that will make it more durable than existing artificial valves; and its frame has built-in joints, making it expandable and facilitating any future re-replacement surgeries that may be necessary. Through a minimally invasive procedure, a larger valve can be placed inside the deteriorating valve when needed.
“In years past, aortic valve replacement typically substituted a mechanical valve for the damaged valve, requiring recipients to be on blood thinners for the rest of their lives,” said Dr. Adam Arnofsky, cardiothoracic surgeon at Englewood Health who performed the procedure, in a prepared statement. “Inspiris has the potential to be a game-changer for patients under the age of 70.”
Englewood Health’s cardiothoracic surgery team is now incorporating the Inspiris valve into its decision-making process when evaluating patients preoperatively.